Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model.
Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van Ek W, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S.
Duiker EW, et al. Among authors: van dam gm, van der zee ag.
Clin Cancer Res. 2009 Mar 15;15(6):2048-57. doi: 10.1158/1078-0432.CCR-08-1535. Epub 2009 Mar 10.
Clin Cancer Res. 2009.
PMID: 19276284
Free article.